DMT7 |
カタログ番号GC92263
One-Click Copy Product Info
|
DMT7 is an ionizable cationic lipid (pKa= 6.5) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and anticancer agents in vivo.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
DMT7 is an ionizable cationic lipid (pKa= 6.5) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and anticancer agents in vivo. LNPs containing DMT7 and encapsulating mRNA encoding Il-12 and the STING agonist MSA-2 decrease tumor volume, lung metastatic nodule numbers, and lung levels of CD4+ and CD8+ T cells in a 4T1 breast cancer mouse xenograft model of lung metastasis. The same LNPs decrease the number of tumor-associated regulatory T cells (Tregs), increase the number of tumor-associated M1 macrophages, and increase intratumoral levels of Il-12, Il-2, Tnf-α, and Ifn-γ in a B16/F10 murine melanoma model.
| Cas No. | SDF | ||
| Chemical Name | 1-(2-(dimethylamino)ethyl)-3-((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl)thiourea | ||
| Canonical SMILES | CCCCC/C=C\C/C=C\CCCCCCCCC(CCCCCCCC/C=C\C/C=C\CCCCC)NC(NCCN(C)C)=S | ||
| Formula | C42H79N3S | M.Wt | 658.2 |
| 溶解度 | DMSO: Sparingly soluble: 1-10 mg/ml; Ethanol: Soluble: ≥10 mg/ml | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.5193 mL | 7.5965 mL | 15.193 mL |
| 5 mM | 303.9 μL | 1.5193 mL | 3.0386 mL |
| 10 mM | 151.9 μL | 759.6 μL | 1.5193 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >90.00% Appearance: A solution in ethanol
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)